Shlomo Yanai is a Senior Advisor at Moelis & Company. Shlomo most recently served as the Chief Executive Officer and President of Teva Pharmaceutical Industries Ltd from 2007 to 2012. Prior to Teva, he served four years as the Chief Executive Officer and President of ADAMA Agricultural Solutions Ltd. During his nearly 15 years as a corporate executive, Shlomo has successfully completed over 20 acquisitions and integrations. Shlomo currently holds board positions at a number of companies and organizations including his role as Non-Executive Chairman of the Board of Directors and member of the Governance and Compensation Committees at Cambrex, Director of Perrigo Public Limited Company, and Chairman of the Board of Directors of Protalix BioTherapeutics.

Shlomo holds a B.A. degree in Political Science and Economics from Tel Aviv University and an M.P.A in National Resources Management from the George Washington University. He is also a graduate of the Advanced Management Program of Harvard Business School and U.S. National War College (NDU).

Elan Zivotofsky is a Managing Director at Moelis & Company where he specializes in providing financial and strategic advice to technology clients. Elan has over 20 years of investment banking experience, specializing in raising capital for and investing in Israeli companies.

Prior to joining Moelis & Company, Elan served as Managing Director at Ibex Investors, where he led the funds’ growth stage venture investments in Israel. Prior to that he was a Founding Partner at OurCrowd, a Jerusalem-based investment platform. Before OurCrowd, Elan was Head of Technology investment banking at Lehman Brothers and previously worked at Goldman Sachs, both in Israel. He began his career at Morgan Stanley in New York. Elan holds a B.A. in History from the University of Pennsylvania.